Clinical Trials Browser

Interventional × Has results × sapanisertib × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Carcinoma, Renal Cell

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Somatostatinoma

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Nonhematological Neoplasms

Advanced Solid Tumors

Carcinoma, Hepatocellular, Liver Neoplasms

Recurrent Lung Squamous Cell Carcinoma

Endometrial Neoplasms

Breast Neoplasms

Carcinoma, Merkel Cell

Advanced Solid Malignancies

Non-hematologic Malignancy

Advanced Nonhematologic Malignancies

Metastatic Castration-Resistant Prostate Cancer

Advanced Nonhematologic Malignancies

Hematologic Neoplasms

Clinical Trials

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

ANETT

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Phase II Study of TAK228 in Relapsed Lymphoma

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies